These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34195239)

  • 41. Non-invasive imaging of bioresorbable coronary scaffolds using CT and MRI: First in vitro experience.
    Hickethier T; Kröger JR; Von Spiczak J; Baessler B; Pfister R; Maintz D; Bunck AC; Michels G
    Int J Cardiol; 2016 Mar; 206():101-6. PubMed ID: 26785034
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.
    Serruys PW; Onuma Y; Ormiston JA; de Bruyne B; Regar E; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Miquel-Hebert K; Rapoza R; García-García HM
    Circulation; 2010 Nov; 122(22):2301-12. PubMed ID: 21098436
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Magmaris: a new generation metallic sirolimus-eluting fully bioresorbable scaffold: present status and future perspectives.
    Rapetto C; Leoncini M
    J Thorac Dis; 2017 Aug; 9(Suppl 9):S903-S913. PubMed ID: 28894596
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neointimal coverage and late apposition of everolimus-eluting bioresorbable scaffolds implanted in the acute phase of myocardial infarction: OCT data from the PRAGUE-19 study.
    Toušek P; Kočka V; Malý M; Lisa L; Buděšínský T; Widimský P
    Heart Vessels; 2016 Jun; 31(6):841-5. PubMed ID: 25896128
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes.
    Serruys PW; Onuma Y; Dudek D; Smits PC; Koolen J; Chevalier B; de Bruyne B; Thuesen L; McClean D; van Geuns RJ; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Sudhir K; Garcia-Garcia HM; Ormiston JA
    J Am Coll Cardiol; 2011 Oct; 58(15):1578-88. PubMed ID: 21958884
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
    Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y
    Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Magnesium 2000 postmarket evaluation: Guideline adherence and intraprocedural performance of a sirolimus-eluting resorbable magnesium scaffold.
    Wlodarczak A; Garcia LAI; Karjalainen PP; Komócsi A; Pisano F; Richter S; Lanocha M; Rumoroso JR; Leung KF
    Cardiovasc Revasc Med; 2019 Dec; 20(12):1140-1145. PubMed ID: 30833209
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fracture with the newer bioresorbable vascular scaffolds.
    Elwany M; Di Palma G; Cortese B
    Catheter Cardiovasc Interv; 2017 Oct; 90(4):582-583. PubMed ID: 28295999
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Two-Year Outcomes for Patients with Non-ST-Elevation Acute Coronary Syndrome Treated with Magmaris and Absorb Bioresorbable Scaffolds in Large-Vessel Lesions.
    Włodarczak A; Rola P; Włodarczak S; Szudrowicz M; Giniewicz K; Łanocha M; Jaroszewska-Pozorska J; Barycki M; Furtan Ł; Kędzierska M; Włodarczak P; Doroszko A; Lesiak M
    J Pers Med; 2024 May; 14(5):. PubMed ID: 38793122
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The DESolve
    Demola P; Meucci F; Stolcova M; Mario CD; Mattesini A
    Future Cardiol; 2021 Sep; 17(6):945-951. PubMed ID: 33507091
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fate of post-procedural malapposition of everolimus-eluting polymeric bioresorbable scaffold and everolimus-eluting cobalt chromium metallic stent in human coronary arteries: sequential assessment with optical coherence tomography in ABSORB Japan trial.
    Sotomi Y; Onuma Y; Dijkstra J; Miyazaki Y; Kozuma K; Tanabe K; Popma JJ; de Winter RJ; Serruys PW; Kimura T
    Eur Heart J Cardiovasc Imaging; 2018 Jan; 19(1):59-66. PubMed ID: 28158421
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative Characterization of Biomechanical Behavior and Healing Profile of a Novel Ultra-High-Molecular-Weight Amorphous Poly-l-Lactic Acid Sirolimus-Eluting Bioresorbable Coronary Scaffold.
    Cheng Y; Gasior P; Shibuya M; Ramzipoor K; Lee C; Estrada EA; Dokko D; McGregor JC; Conditt GB; Kaluza GL; Granada JF
    Circ Cardiovasc Interv; 2016 Oct; 9(10):. PubMed ID: 27694138
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial.
    Suwannasom P; Sotomi Y; Ishibashi Y; Cavalcante R; Albuquerque FN; Macaya C; Ormiston JA; Hill J; Lang IM; Egred M; Fajadet J; Lesiak M; Tijssen JG; Wykrzykowska JJ; de Winter RJ; Chevalier B; Serruys PW; Onuma Y
    JACC Cardiovasc Interv; 2016 Jun; 9(12):1231-1242. PubMed ID: 27262861
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro and in vivo evaluation of a novel bioresorbable magnesium scaffold with different surface modifications.
    Menze R; Wittchow E
    J Biomed Mater Res B Appl Biomater; 2021 Sep; 109(9):1292-1302. PubMed ID: 33386677
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Resorbable Magnesium Scaffold Magmaris in Acute Coronary Syndrome: An Appraisal of Evidence and User Group Guidance.
    Bennett J; Ielasi A; Torzewski J; de Hemptinne Q; Cerrato E; Lanocha M; Galli S; Sabaté M
    Cardiovasc Revasc Med; 2022 Jun; 39():106-113. PubMed ID: 34629285
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Magmaris very late in-scaffold restenosis: Has the "black boxes" nightmare come back?
    Bayón J; Santás-Álvarez M; Ocaranza-Sánchez R; González-Juanatey C
    Catheter Cardiovasc Interv; 2020 Aug; 96(2):E174-E176. PubMed ID: 31763757
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study.
    Diletti R; Karanasos A; Muramatsu T; Nakatani S; Van Mieghem NM; Onuma Y; Nauta ST; Ishibashi Y; Lenzen MJ; Ligthart J; Schultz C; Regar E; de Jaegere PP; Serruys PW; Zijlstra F; van Geuns RJ
    Eur Heart J; 2014 Mar; 35(12):777-86. PubMed ID: 24394380
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Major coronary evaginations following implantation of bioresorbable vascular scaffolds - Clinical and OCT characteristics.
    Blachutzik F; Achenbach S; Marwan M; Röther J; Tröbs M; Schneider R; Nef H; Weissner M; Schlundt C
    Cardiovasc Revasc Med; 2019 Jun; 20(6):485-491. PubMed ID: 30097188
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neointimal Healing Evaluated by Optical Coherence Tomography after Drug-Eluting Absorbable Metal Scaffold Implantation in de novo Native Coronary Lesions: Rationale and Design of the Magmaris-OCT Study.
    Karjalainen P; Paana T; Sia J; Nammas W
    Cardiology; 2017; 137(4):225-230. PubMed ID: 28467998
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of Side-Branch Dilation Techniques After Resorbable Magnesium Scaffold Implantation: A Bench Study.
    de Pommereau A; Mogi S; de Hemptinne Q; Adjedj J; Varenne O; Picard F
    J Invasive Cardiol; 2019 Aug; 31(8):E249-E255. PubMed ID: 31368896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.